ErVaccine Technologies announces the publication of a new paper in European Journal of Cancer journal
June 16, 2022

ErVaccine Technologies, a preclinical-stage biotechnology company, today announces the publication of a new paper in European Journal of Cancer journal: ‘Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy’ demonstrating that therapeutic vaccines should be considered in the context of low or moderate tumour burden, whereas TCR-engineered T cell strategies may be more adapted for the treatment of advanced / metastatic diseases.

ErVaccine evaluated the relationship between tumour burden, number of effector T cells and clinical outcome after vaccine and adoptive T cell therapy by performing a meta-analysis of previously published and available clinical data and applying a mathematical model for tumour immune dynamics. ErVaccine envisions that a vaccine approach in combination with TCR-engineered T cells may not only stimulate the latter but also prime endogenous T cells to collaborate with transferred T cells, a major breakthrough in cancer treatment!

Click here to read the article

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact



+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go